Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewRAGE antagonist peptide
说明： RAGE antagonist
纯度： ≥95% (HPLC)
生物活性 for RAGE antagonist peptide
RAGE antagonist peptide is a receptor for advanced glycation end products (RAGE) antagonist. Blocks S100P, S100A4 and HMGB-1 mediated RAGE activation in vitro and in vivo. Inhibits growth and metastasis of rat glioma tumors. Reduces cell growth and RAGE-mediated NF-κB activity in human PDAC cell lines. Inhibits effects of TDI exposure in BALB/c mice.
技术数据 for RAGE antagonist peptide
| 分子量 | 1272.56 |
| 公式 | C57H101N13O17S |
| 序列 |
ELKVLMEKEL (Modifications: Glu-1 = N-terminal Ac, Leu-10 = C-terminal amide) |
| 储存 | Store at -20°C |
| 纯度 | ≥95% (HPLC) |
| CAS Number | 1092460-91-7 |
| PubChem ID | 127021052 |
| InChI Key | UPCWJIBXKJZZLN-YZLORNOTNA-N |
| Smiles | CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(C)=O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(N)=O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for RAGE antagonist peptide
| 溶解性 | Soluble to 1 mg/ml in water |
产品说明书 for RAGE antagonist peptide
参考文献 for RAGE antagonist peptide
参考文献是支持产品生物活性的出版物。
Arumugam et al (2012) S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin.Cancer.Res. 18 4356 PMID: 22718861
Yao et al (2016) The receptor for advanced glycation end products is required for beta -catenin stabilization in a chemical-induced asthma model. Br.J.Pharmacol. 173 2600 PMID: 27332707
If you know of a relevant reference for RAGE antagonist peptide, please let us know.
按标靶查看相关产品
按产品操作查看相关产品
关键词: RAGE antagonist peptide, RAGE antagonist peptide supplier, Inhibitors, Inhibits, Antagonist, RAGE, Receptor, for, advanced, glycation, end, products, RAP, antagonist, peptide, NF-kB/IkB, 6259, Tocris Bioscience
2 篇 RAGE antagonist peptide 的引用文献
引用文献是使用了 Tocris 产品的出版物。 RAGE antagonist peptide 的部分引用包括：
Thom et al (2023) Blood-Borne Microparticles Are an Inflammatory Stimulus in Type 2 Diabetes Mellitus Immunohorizons 7 71 PMID: 36645851
Uderhardt et al (2019) Resident Macrophages Cloak Tissue Microlesions to Prevent Neutrophil-Driven Inflammatory Damage. Cell 177 541 PMID: 30955887
您是否知道使用了 Tocris RAGE antagonist peptide 的优秀论文？ 请告知我们.
RAGE antagonist peptide 的评论
平均评分: 5 (Based on 1 Review.)
Have you used RAGE antagonist peptide?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Good inhibitor.
By
Stefan Uderhardt on 06/06/2020
分析类型： In Vivo
种属： Mouse
细胞系/组织： phagocyte
H20 dilution 10 μM
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Multiple Sclerosis Poster
Multiple sclerosis (MS) is an autoimmune disease that is characterized by focal demyelination and axon degeneration in the central nervous system. This poster summarizes the neurobiology and current therapies of MS.
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.